Treatment of relapsed precursor-b acute lymphoblastic leukemia with intensive chemotherapy: Pog (pediatric oncology group) study 9411 (SIMAL 9)

Michael E. Kelly, Xiaomin Lu, Meenakshi Devidas, Bruce Camitta, Thomas Abshire, Mark L. Bernstein, Amy Billett, Alan Homans, Eric Sandler, George Buchanan

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Pediatric patients who experience a bone marrow relapse of precursor-B acute lymphoblastic leukemia are cured <50% of the time. This study was designed to determine if intensification of therapies with known activity in this disease would improve the cure rates for patients with relapsed acute lymphoblastic leukemia. Patients were treated with intensive asparaginase during induction followed by repeated cycles of ifosfamide/etoposide and cytarabine/idarubicin. Patients with well-matched related donors were encouraged to undergo hematopoietic stem cell transplant as consolidation. The results of this study demonstrate no significant difference in disease-free survival in patients who received chemotherapy alone (45%) or chemotherapy followed by allogeneic stem cell transplant (50%). Furthermore, results from this study show no significant difference in event-free survival (39.9%±6.2%) or overall survival (41.6%±6.1%) at 8 years when compared with previous studies using less intensive regimens. Our results suggest that alternative therapies are needed to improve cure rates for pediatric patients with relapsed leukemia.

Original languageEnglish (US)
Pages (from-to)509-513
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume35
Issue number7
DOIs
StatePublished - Oct 1 2013

Keywords

  • ALL
  • POG study 9411
  • SIMAL 9
  • intensive chemotherapy
  • relapsed precursor-B

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Treatment of relapsed precursor-b acute lymphoblastic leukemia with intensive chemotherapy: Pog (pediatric oncology group) study 9411 (SIMAL 9)'. Together they form a unique fingerprint.

  • Cite this